<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="182517">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718380</url>
  </required_header>
  <id_info>
    <org_study_id>M10-227</org_study_id>
    <nct_id>NCT00718380</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of ABT-869 in Subjects With Solid Tumors</brief_title>
  <official_title>An Open Label, Phase I Study Evaluating Pharmacokinetics, Safety, and Tolerability of ABT-869 in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the pharmacokinetics, safety and tolerability of
      ABT-869 in Japanese patients with solid tumors up to the Recommended Phase Two Dose that was
      determined in a previous the M04-710 study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety tolerability assessment</measure>
    <time_frame>Weekly assessment for 3 weeks then every 3 weeks or more frequently as needed</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicity determination</measure>
    <time_frame>Weekly assessment for the first 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile evaluation</measure>
    <time_frame>Day 1 and Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary tumor response</measure>
    <time_frame>Every 6 week</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation from Open label 0.05 to 0.25 mg/kg once a day dosing for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label 0.10 mg/kg once a day dosing after safety evolution of Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label 0.20 mg/kg once a day dosing after safety evolution of Group 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label 0.25 mg/kg once a day dosing after safety evolution of Group 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-869</intervention_name>
    <description>2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subjects aged from 20 to 75 years and ECOG PS of 0-2 at screening.

          -  Subject must have a solid tumor that is refractory to standard therapies or for which
             a standard effective therapy does not exist.

          -  The subject must have adequate bone marrow, renal and hepatic function.

          -  Women of child-bearing potential and men must agree to use adequate contraception
             prior to study entry, for the duration of study participation and up to six months
             following completion of therapy.

          -  The subject must voluntarily sign and date an informed consent.

        Exclusion Criteria

          -  The subject currently exhibits symptomatic or intervention indicated CNS metastasis.

          -  The subject has received any anti-cancer therapy including chemotherapy,
             immunotherapy, radiotherapy, hormonal, biologic or any investigational therapy within
             4 weeks of enrollment or has not fully recovered from toxicity resulting from past
             treatment(s) that affects the assessments in this study at the enrollment.

          -  The subject with the following conditions during screening assessment.

               1. proteinuria CTC grade &gt; 1 as measured by urinalysis and 24 hour urine collection

               2. diastolic blood pressure (BP) &gt; 95 mmHg; or systolic blood pressure (BP) &gt; 150
                  mmHg

               3. a history of or currently exhibits clinically significant cancer related events
                  of bleeding

               4. LV Ejection Fraction &lt; 50%

               5. received a cumulative dose of Anthracycline &gt; 360 mg/m2 for treatment of cancer

               6. receiving therapeutic anticoagulation therapy

               7. having fractures except for chronic bone lesion due to bone metastases

          -  The subject exhibits evidence of other clinically significant uncontrolled
             condition(s).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susumu Matsuki, BS</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Japan Co.,Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 6891</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 13, 2012</lastchanged_date>
  <firstreceived_date>July 16, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
